Denmark's Novo Nordisk, the world's biggest maker of insulin, said on Tuesday a new study showed its long-acting insulin Levemir reduces body weight and improves blood glucose levels in type 2 diabetes patients.
The new data, a subanalysis of 2,377 patients from a larger multinational study, indicated that individuals taking Levemir lost 0.7 kilograms after 14 weeks, compared to a baseline.
"The weight loss was more pronounced in those who entered the trial at higher weight," Novo said in a statement.
The data was presented on Tuesday at the world congress of the International Diabetes Federation in Capetown, South Africa.